Acquired Mutation in BCL2 Confers Resistance to Tx in Progressive CLL

Researchers analyzed a new recurrentBCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.

Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news